Focal Segmental Glomerulosclerosis clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 1-65
This is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in children and adults.
Davis, California and other locations
Our lead scientists for Focal Segmental Glomerulosclerosis research studies include Junichuro Sageshima, MD.